SEPT6-ABL2 fusion for use in the diagnosis and/or treatment of cancer

Patent number:

PCT/EP2022/065750; EP21382663

Comunidad de Madrid.svg
No items found.

The present invention refers to a cell line characterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2], and also to the use of [SEPT6-ABL2] fusion in a method for the diagnosis and/or treatment of cancer.

Countries:
Spain
Regions:
Community of Madrid
Centers:
UNIVERSIDAD AUTONOMA DE MADRID, FUNDACION INSTITUTO DE INVESTI GACION SANITARIA FUNDACION JIMENEZ DIAZ
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 5 – technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies)
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
SDG03: Good health and well-being
Applications

The present invention refers to the medical field. Particularly, the present invention refers to a cell line characterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2]. The present invention is also focused on the use of SEPT6-ABL2 fusion in a method for the diagnosis and/or treatment of cancer.

Comments

Other related patents

Health

Device for converting a surgical instrument into a spreader

Countries
Spain
Know more
Other
Health
Telecom

METHOD AND SYSTEM FOR GENERATING HANDWRITTEN TEXT WITH DIFFERENT DEGREES OF MATURITY OF THE WRITER

Countries
Spain
Know more
Health

SIMULTANEOUS DETECTION OF CHROMOSOMAL ALTERATIONS THROUGH MAGNETIC CAPTURE, MICROSCOPY AND FLOW CYTOMETRY

Countries
Spain
Know more
Get back to patents directory